Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $537.10M
• Dividend Yield: N/A
• Average Volume (3M): 247.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: 3.01%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 53,177,990
• 10 Day Avg. Volume: 207,541
• 30 Day Avg. Volume: 247,118
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.90K
• Enterprise Value/Ebitda: -2.11
• 1Y Price Target: $30.25
• Price Target Upside: 199.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 41 Neutral
• Price Target: ―

Tyra Bioscience's overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.

Positive Factors

Clinical Trials

TYRA-300 led to an impressive 55% ORR in FGFR3+ mUC patients dosed with >90mg, which is significantly higher than erda's ~35% ORR.

Economic Incentives

There may be an important economic incentive for community urologists to prescribe TYRA-300, as it may be prescribed through a popular group purchasing organization, called UroGPO.

Market Position

TYRA-300 should offer a unique competitive angle in NMIBC, if it is ultimately successful in clinical development.

Negative Factors

Efficacy Comparison

The delta between the 35% overall response rate for Balversa and 55% for TYRA-300 is quite wide, implying a wide margin for positive data.

Regulatory

Management announced FDA acceptance of an IND for a Phase II study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer, which will enroll up to 90 participants throughout the US.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

How the Company Makes Money

Tyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary

Tyra Bioscience's financials reflect its focus on research and development in the biotechnology sector. The lack of revenue and increasing losses are typical of a company investing heavily in future growth. While the company maintains strong liquidity through cash reserves, its reliance on external financing and negative profit margins indicate a high-risk profile. Investors should monitor the company's progress towards revenue generation and cost management to assess future financial health.

Income Statement

Tyra Bioscience has consistently reported zero revenue, which is typical for early-stage biotechnology firms focusing on research and development. The company shows increasing losses over the years, with a notable rise in EBIT and net losses, indicating higher operational expenses. This results in negative profit margins, reflecting the company's developmental stage and need for capital investment.

Balance Sheet

The balance sheet shows strong liquidity with significant cash and short-term investments, outpacing total debt, resulting in negative net debt. The equity ratio is robust, showing a high proportion of assets financed by equity, which is positive for stability. However, the company's negative stockholders' equity in previous years reflects accumulated losses, posing a potential risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow, typical for a company in the R&D phase. The high free cash flow outflow, though concerning, is offset by strong financing cash flow, suggesting reliance on external funding. The absence of revenue growth limits free cash flow growth, highlighting reliance on external capital to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-353.00K	-296.00K	-140.00K	-47.00K
EBITDA	-85.96M	-79.59M	-58.63M	-26.15M	-9.25M
Net Income	-86.48M	-69.13M	-51.72M	-26.14M	-9.31M
Balance Sheet
Total Assets	363.56M	225.86M	266.18M	306.70M	16.01M
Cash, Cash Equivalents and Short-Term Investments	341.44M	203.47M	251.21M	302.18M	15.22M
Total Debt	6.22M	6.50M	2.62M	1.18M	142.00K
Total Liabilities	20.41M	21.59M	8.35M	4.96M	29.65M
Stockholders Equity	343.15M	204.26M	-95.70M	301.74M	-13.64M
Cash Flow
Free Cash Flow	-70.44M	-50.91M	-50.84M	-24.41M	-8.07M
Operating Cash Flow	-69.77M	-50.14M	-50.28M	-23.75M	-7.76M
Investing Cash Flow	-98.40M	-144.60M	-559.00K	-645.00K	-312.00K
Financing Cash Flow	202.14M	1.54M	632.00	311.35M	23.43M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Negative. The current price of 10.1 is below the 20-day moving average (MA) of 10.75, below the 50-day MA of 10.27, and below the 200-day MA of 12.42, indicating a bearish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 25.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBPH	57 Neutral	$576.02M	―	6.23%	―	24.49%	―
SAGE	54 Neutral	$543.61M	―	-60.43%	―	-27.59%	34.00%
MGTX	54 Neutral	$630.06M	―	-216.14%	―	203.23%	-80.71%
Sector *	50 Neutral	AU$2.58B	2.96	5.87%	2.70%	36.78%	14.04%
KROS	48 Neutral	$542.22M	42.61	3.33%	―	85820.30%	―
TYRA	41 Neutral	$537.10M	―	-27.04%	―	―	3.01%
MNMD	40 Neutral	$749.47M	―	-59.11%	―	―	39.66%

Tyra Bioscience Corporate Events

Tyra Biosciences Appoints Adele M. Gulfo to Board

Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.